Your session is about to expire
← Back to Search
Antifibrinolytic agent
Tranexamic Acid for Hip Fracture
N/A
Waitlist Available
Research Sponsored by Rothman Institute Orthopaedics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients admitted to Bryn Mawr Hospital with fracture of the femoral neck, intertrochanteric region, or subtrochanteric region of the femur will be considered for the study.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up participants will be followed for the duration of hospital stay, an expected average of 2-3 days
Awards & highlights
Study Summary
This trial is investigating whether a drug that inhibits blood loss (Tranexamic acid) is effective in decreasing blood loss and transfusion requirement in hip fracture patients.
Who is the study for?
This trial is for patients at Bryn Mawr Hospital with a hip fracture in specific regions of the femur. It's not for those with blood clots, bleeding disorders, hormone therapy users, kidney failure (creatinine clearance <30 ml/min), pregnant or breastfeeding women, under 18s, multiple fractures cases, nonoperative fracture management plans, seizure history or TA allergy.Check my eligibility
What is being tested?
The study tests if Tranexamic Acid (TA) can reduce blood loss and need for transfusions after hip fracture surgery. Patients will either receive TA or saline as a control to compare outcomes. The focus is on whether TA's benefits in elective joint replacement also apply to these emergency cases.See study design
What are the potential side effects?
Tranexamic Acid may cause side effects such as increased risk of blood clots and seizures; however, it is generally well-tolerated when used correctly. This study excludes individuals with conditions that increase these risks.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am admitted to Bryn Mawr Hospital with a specific type of thigh bone fracture.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ participants will be followed for the duration of hospital stay, an expected average of 2-3 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~participants will be followed for the duration of hospital stay, an expected average of 2-3 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
calculation of blood loss during the perioperative period
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: InterventionalActive Control1 Intervention
Group II: ControlPlacebo Group1 Intervention
Find a Location
Who is running the clinical trial?
Rothman Institute OrthopaedicsLead Sponsor
121 Previous Clinical Trials
21,578 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My fracture will be treated without surgery.I am admitted to Bryn Mawr Hospital with a specific type of thigh bone fracture.I have had multiple broken bones.I am younger than 18 years old.I have a history of blood clots in my veins.I have a known bleeding or clotting disorder.I have had seizures in the past.I am currently experiencing bleeding in the brain.I am currently using estrogen/progesterone therapy.My kidney function is low, with a creatinine clearance under 30 ml/min.
Research Study Groups:
This trial has the following groups:- Group 1: Control
- Group 2: Interventional
Awards:
This trial has 1 awards, including:- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
To what ailments can Interventional be applied to provide relief?
"Interventional is a highly effective treatment for hyperfibrinolysis, as well as hemophilia, dental extractions, and bleeding."
Answered by AI
Are there other investigations involving Interventional that have been conducted prior to this one?
"Currently, 61 trials are ongoing for Interventional treatments with 26 of these studies in Phase 3. The greatest concentration of centres is located in Kansas City, however there are 185 other sites running this type of trial across the globe."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger